1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Biotec Pharmacon ASA – Product Pipeline Review – 2013

Biotec Pharmacon ASA – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 36 pages

Biotec Pharmacon ASA – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Biotec Pharmacon ASA - Product Pipeline Review - 2013” provides data on the Biotec Pharmacon ASA’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Biotec Pharmacon ASA’s corporate website, SEC filings, investor presentations and featured press releases, both from Biotec Pharmacon ASA and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Biotec Pharmacon ASA - Brief Biotec Pharmacon ASA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biotec Pharmacon ASA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Biotec Pharmacon ASA with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Biotec Pharmacon ASA’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Biotec Pharmacon ASA’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Biotec Pharmacon ASA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Biotec Pharmacon ASA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Biotec Pharmacon ASA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Biotec Pharmacon ASA and identify potential opportunities in those areas.

Table Of Contents

Biotec Pharmacon ASA - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Biotec Pharmacon ASA Snapshot 4
Biotec Pharmacon ASA Overview 4
Key Information 4
Key Facts 4
Biotec Pharmacon ASA - Research and Development Overview 5
Key Therapeutic Areas 5
Biotec Pharmacon ASA - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Combination Treatment Modalities 9
Biotec Pharmacon ASA - Pipeline Products Glance 10
Biotec Pharmacon ASA Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Biotec Pharmacon ASA - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Biotec Pharmacon ASA - Drug Profiles 12
Soluble Beta Glucan 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Soluble Beta Glucan + [rituximab] 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Biotec Pharmacon ASA - Pipeline Products by Route of Administration 17
Biotec Pharmacon ASA - Recent Pipeline Updates 18
Biotec Pharmacon ASA - Dormant Projects 19
Biotec Pharmacon ASA - Discontinued Pipeline Products 20
Discontinued Pipeline Product Profiles 20
Soluble Beta Glucan 20
Biotec Pharmacon ASA - Locations And Subsidiaries 21
Head Office 21
Financial Deals Landscape 22
Biotec Pharmacon ASA, Deals Summary 22
Biotec Pharmacon ASA, Pharmaceuticals and Healthcare, Deal Details 23
Equity Offering 23
Biotec Pharmacon Completes Rights Offering Of Shares For US$2 Million 23
Biotec Pharmacon Completes Private Placement Of Shares For US$7 Million 25
Biotec Pharmacon Completes Rights Offering Of Shares For US$1.3 Million 27
Biotec Pharmacon Completes Private Placement Of US$3.68 Million 29
Biotec Pharmacon Completes Private Placement Of Stock For US$20 Million 31
Acquisition 33
SANA Pharma Acquires Immunocorp Consumer Health and Immunocorp from Biotec Pharmacon ASA 33
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36



List of Tables

Biotec Pharmacon ASA, Key Information 4
Biotec Pharmacon ASA, Key Facts 4
Biotec Pharmacon ASA - Pipeline by Indication, 2013 6
Biotec Pharmacon ASA - Pipeline by Stage of Development, 2013 7
Biotec Pharmacon ASA - Monotherapy Products in Pipeline, 2013 8
Biotec Pharmacon ASA - Combination Treatment Modalities in Pipeline, 2013 9
Biotec Pharmacon ASA - Phase I, 2013 10
Biotec Pharmacon ASA - Pre-Clinical, 2013 11
Biotec Pharmacon ASA - Pipeline By Route of Administration, 2013 17
Biotec Pharmacon ASA - Recent Pipeline Updates, 2013 18
Biotec Pharmacon ASA - Dormant Developmental Projects,2013 19
Biotec Pharmacon ASA - Discontinued Pipeline Products, 2013 20
Biotec Pharmacon ASA, Deals Summary 22
Biotec Pharmacon Completes Rights Offering Of Shares For US$2 Million 23
Biotec Pharmacon Completes Private Placement Of Shares For US$7 Million 25
Biotec Pharmacon Completes Rights Offering Of Shares For US$1.3 Million 27
Biotec Pharmacon Completes Private Placement Of US$3.68 Million 29
Biotec Pharmacon Completes Private Placement Of Stock For US$20 Million 31
SANA Pharma Acquires Immunocorp Consumer Health and Immunocorp from Biotec Pharmacon ASA 33



List of Figures

Biotec Pharmacon ASA - Pipeline by Indication, 2013 6
Biotec Pharmacon ASA - Pipeline by Stage of Development, 2013 7
Biotec Pharmacon ASA - Monotherapy Products in Pipeline, 2013 8
Biotec Pharmacon ASA - Combination Treatment Modalities in Pipeline, 2013 9

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Nordic Nanovector ASA (NANO) - Financial and Strategic SWOT Analysis Review

Nordic Nanovector ASA (NANO) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Nordic Nanovector ASA (Nordic Nanovector) formerly Nordic Nanovector AS, is a biotechnology company which develops and commercializes antibody radionuclide conjugates (ARC) for the treatment of ...

PCI Biotech Holding ASA (PCIB) - Financial and Strategic SWOT Analysis Review

PCI Biotech Holding ASA (PCIB) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary PCI Biotech Holding ASA (PCI Biotech) a subsidiary of Photocure ASA is a biopharmaceutical company that offers cancer care solutions. The company offers development of therapeutic products based ...

Targovax ASA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Targovax ASA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • September 2016
  • by Global Data

Summary Targovax ASA (Targovax) is a clinical stage immuno-oncology company that focuses on the design and development of immunotherapy treatments for cancer patients. The company’s pipeline products ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.